Jun 17, 2020

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 2: A roundtable discussion featuring Borghaei, Brahmer, Garon and Govindan.

• Genomic profiling for patients with metastatic NSCLC; role of liquid biopsy (00:00)
• Therapeutic approach for patients with NSCLC with no targetable mutations (10:02)
• Case (Dr Deutsch): A woman in her late 60s with metastatic squamous cell carcinoma of the lung and a high PD-L1 tumor proportion score (TPS) of 60% initially treated with pembrolizumab monotherapy receives carboplatin/paclitaxel and maintenance pembrolizumab upon disease progression (21:32)
• Case (Dr Picton): A man in his mid-80s and previous smoker receives carboplatin/paclitaxel/pembrolizumab as first-line therapy for metastatic squamous cell carcinoma of the lung (27:35)
• Selection of second-line therapy for patients with metastatic nonsquamous NSCLC; benefits and risks with the addition of ramucirumab to docetaxel (32:17)
• Perspective on the use of bevacizumab or ramucirumab in combination with an immune checkpoint inhibitor and chemotherapy for metastatic NSCLC (37:03)
• Case (Dr Martins): A man in his early 70s and previous smoker with metastatic nonsquamous NSCLC develops diarrhea with bleeding after receiving first-line pembrolizumab (45:42)
• Screening and clinical care of patients with lung cancer during the COVID-19 pandemic (48:59)
• Case (Dr Picton): A woman in her early 50s with metastatic squamous NSCLC with a BRAF tumor mutation receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pemetrexed/pembrolizumab and develops immune-related colitis (55:18)
• Management of metastatic NSCLC with targetable EGFR mutations (1:01:56)
• Case (Dr Deutsch): A woman in her late 40s and never smoker with metastatic adenocarcinoma of the lung with an EGFR tumor mutation develops a T790M mutation 2 years after treatment with erlotinib and bevacizumab on a clinical trial (1:11:18)

CME information and select publications